keyword
MENU ▼
Read by QxMD icon Read
search

ASCO

keyword
https://www.readbyqxmd.com/read/28441112/second-line-hormonal-therapy-for-men-with-chemotherapy-na%C3%A3-ve-castration-resistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion
#1
Katherine S Virgo, Ethan Basch, D Andrew Loblaw, Tom Oliver, R Bryan Rumble, Michael A Carducci, Luke Nordquist, Mary-Ellen Taplin, Eric Winquist, Eric A Singer
Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publication or presentation of potential practice-changing data. This PCO addresses second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer (CRPC) who range from being asymptomatic with only biochemical evidence of CRPC to having documented metastases but minimal symptoms. Clinical Context The treatment goal for CRPC is palliation. Despite resistance to initial androgen deprivation therapy, most men respond to second-line hormonal therapies...
April 25, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28437162/adjuvant-systemic-therapy-and-adjuvant-radiation-therapy-for-stage-i-to-iiia-completely-resected-non-small-cell-lung-cancers-american-society-of-clinical-oncology-cancer-care-ontario-clinical-practice-guideline-update
#2
Mark G Kris, Laurie E Gaspar, Jamie E Chaft, Erin B Kennedy, Christopher G Azzoli, Peter M Ellis, Steven H Lin, Harvey I Pass, Rahul Seth, Frances A Shepherd, David R Spigel, John R Strawn, Yee C Ung, Michael Weyant
Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell lung cancers. Methods ASCO convened an update panel and conducted a systematic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers. Results The updated evidence base covered questions related to adjuvant systemic therapy and included a systematic review conducted by Cancer Care Ontario current to January 2016. A recent American Society for Radiation Oncology guideline and systematic review, previously endorsed by ASCO, was used as the basis for recommendations for adjuvant radiation therapy...
April 24, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28433541/the-impact-of-2013-updated-asco-cap-her2-guidelines-on-the-diagnosis-and-management-of-invasive-breast-cancer-a-single-center-study-of-1739-cases
#3
Xiaofei Zhang, Ira Bleiweiss, Shabnam Jaffer, Anupma Nayak
BACKGROUND: The purpose of this study was to determine the impact of revised ASCO/CAP 2013 HER2 guidelines on the clinical practice of pathologists and oncologists. MATERIALS AND METHODS: Retrospective analysis of 1739 patients with invasive breast carcinoma who underwent reflex HER2 (fluorescence in situ hybridization [FISH]) testing, using both 2007 and 2013 guidelines (2007-2014). RESULTS: Using 2013 guidelines, 255 (15%; 95% confidence interval [CI], 13%-16%) cases were classified as HER2(+) as opposed to 186 (11%; 95% CI, 9%-12%) by 2007 guidelines (odds ratio [OR] 1...
March 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28427161/efficacy-of-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitors-tkis-in-targeted-therapy-of-lung-squamous-cell-carcinoma-patients-with-egfr-mutation-a-pooled-analysis
#4
Jingqi Zhuang, Yongfeng Yu, Ziming Li, Shun Lu
PURPOSE: This pooled analysis aims to evaluate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in lung squamous cell carcinoma with EGFR mutation. METHODS: Advanced stage (IIIB/IV) lung squamous cell carcinoma patients with EGFR mutations treated with EGFR-TKIs were extracted from the publications searched from the databases of EMBASE, Medline (Ovid SP), Web of Science, Cochrane library, PubMed Publisher, ASCO meeting abstract and Google Scholar before August 2016, or identified from the database of Shanghai Chest Hospital from July 2014 to August 2016...
February 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28409248/-radiotherapy-for-glioblastoma-asco-endorses-the-astro-guideline
#5
Clemens Seidel, Rolf-Dieter Kortmann
No abstract text is available yet for this article.
April 13, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28399381/adjuvant-chemotherapy-for-stage-ii-colon-cancer-a-clinical-dilemma
#6
Joseph Kannarkatt, Joe Joseph, Peter C Kurniali, Anas Al-Janadi, Borys Hrinczenko
The decision to treat a patient with stage II colon cancer with adjuvant chemotherapy can be challenging. Although the benefit of treatment is clear in most patients with stage III disease, the decision to provide chemotherapy after surgical resection in stage II disease must be made on an individual basis. Several trials have demonstrated the small but absolute benefits of receiving adjuvant chemotherapy for stage II colon cancer for disease-free survival and overall survival. In an attempt to better understand the role of chemotherapy, several studies were performed that identified high-risk characteristics that can be used prognostically and predictively to aid in the clinical decision making process...
April 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28398845/potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update
#7
Alok A Khorana, Pamela B Mangu, Jordan Berlin, Anitra Engebretson, Theodore S Hong, Anirban Maitra, Supriya G Mohile, Matthew Mumber, Richard Schulick, Marc Shapiro, Susan Urba, Herbert J Zeh, Matthew H G Katz
Purpose To update the Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31, 2016. The October 2016 update focuses solely on new evidence that pertains to clinical question 4 of the guideline: What is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumor? Methods The recently published results of a randomized phase III study prompted an update of this guideline...
April 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28368670/american-society-of-clinical-oncology-position-statement-strategies-for-reducing-cancer-health-disparities-among-sexual-and-gender-minority-populations
#8
Jennifer Griggs, Shail Maingi, Victoria Blinder, Neelima Denduluri, Alok A Khorana, Larry Norton, Michael Francisco, Dana S Wollins, Julia H Rowland
ASCO is committed to addressing the needs of sexual and gender minority (SGM) populations as a diverse group at risk for receiving disparate care and having suboptimal experiences, including discrimination, throughout the cancer care continuum. This position statement outlines five areas of recommendations to address the needs of both SGM populations affected by cancer and members of the oncology workforce who identify as SGM: (1) patient education and support; (2) workforce development and diversity; (3) quality improvement strategies; (4) policy solutions; and (5) research strategies...
April 3, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28363514/voxel-based-lesion-mapping-of-cryptogenic-stroke-in-patients-with-advanced-cancer-a-detailed-magnetic-resonance-imaging-analysis-of-distribution-pattern
#9
Takamune Achiha, Masatoshi Takagaki, Hiroshi Oe, Mio Sakai, Hitoshi Matsui, Katsuhiko Nakanishi, Tomohiko Ozaki, Yasunori Fujimoto, Toshiki Yoshimine, Katsuyuki Nakanishi, Manabu Kinoshita
BACKGROUND: Ischemic stroke is one form of cancer-associated thrombosis that can greatly worsen a patient's performance status. The present investigation aimed to elucidate the characteristic distribution pattern(s) of cryptogenic stroke lesions using a voxel-based lesion-mapping technique and examine the differences in clinical manifestations between cryptogenic and conventional strokes in patients with advanced cancer. METHODS: Data from 43 patients with advanced cancer who developed acute ischemic stroke were retrospectively collected...
March 28, 2017: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/28358653/untapped-potential-of-observational-research-to-inform-clinical-decision-making-american-society-of-clinical-oncology-research-statement
#10
Kala Visvanathan, Laura A Levit, Derek Raghavan, Clifford A Hudis, Sandra Wong, Amylou Dueck, Gary H Lyman
ASCO believes that high-quality observational studies can advance evidence-based practice for cancer care and are complementary to randomized controlled trials (RCTs). Observational studies can generate hypotheses by evaluating novel exposures or biomarkers and by revealing patterns of care and relationships that might not otherwise be discovered. Researchers can then test these hypotheses in RCTs. Observational studies can also answer or inform questions that either have not been or cannot be answered by RCTs...
March 30, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28353591/systematic-review-and-meta-analysis-of-preoperative-chemoradiotherapy-with-or-without-oxaliplatin-in-locally-advanced-rectal-cancer
#11
REVIEW
Jiabin Zheng, Xingyu Feng, Weixian Hu, Junjiang Wang, Yong Li
BACKGROUND: Preoperative chemoradiotherapy has become the current standard regimen for locally advanced rectal cancer (LARC). However, the additional benefit of oxaliplatin to preoperative chemotherapy was still controversial. On one hand, oxaliplatin may improve the tumor response rate of even prolong the survival time. On the other hand, it can bring a series of adverse effects. Opinions vary from studies to studies. We aim to perform a meta-analysis to evaluate the efficacy, safety, and long-term survival of oxaliplatin in preoperative chemoradiotherapy for LARC...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28346805/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncology-cancer-care-ontario-joint-guideline-update
#12
Joseph Chin, R Bryan Rumble, Marisa Kollmeier, Elisabeth Heath, Jason Efstathiou, Tanya Dorff, Barry Berman, Andrew Feifer, Arthur Jacques, D Andrew Loblaw
Purpose To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence. Methods An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) with brachytherapy in men with prostate cancer. Results Five randomized controlled trials provided the evidence for this update. Recommendations For patients with low-risk prostate cancer who require or choose active treatment, low-dose rate brachytherapy (LDR) alone, EBRT alone, and/or radical prostatectomy (RP) should be offered to eligible patients...
March 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28345445/the-role-of-patient-financial-assistance-programs-in-reducing-costs-for-cancer-patients
#13
Leah L Zullig, Steven Wolf, Lisa Vlastelica, Veena Shankaran, S Yousuf Zafar
BACKGROUND: Limited transparency exists regarding eligibility and benefits for patient financial assistance programs (PAPs). OBJECTIVE: To describe oral anticancer medication costs, insurance coverage, and the degree of financial assistance provided by PAPs. METHODS: This was a retrospective study of prescription anticancer medication costs and PAP coverage. The study used data from an academic cancer center's specialty pharmacy. Medication, cost, and coverage data were collected from the specialty pharmacy database for prescriptions filled from January 2013 to November 2015...
April 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28341657/effect-of-fixation-time-on-breast-biomarker-expression-a-controlled-study-using-cell-line-derived-xenografted-cdx-tumours
#14
K R Kao, T Hasan, A Baptista, T Truong, L Gai, A C Smith, S Li, P Gonzales, K Voisey, P Eriwvo, J Power, N Denic
AIMS: Altering the length of time specimens are placed in fixative without compromising analytical testing accuracy is a continuous challenge in the anatomical pathology lab. The aim of this study was to determine under controlled conditions the effects of variable fixation time on breast biomarker expression in human breast cancer cell line-derived xenografted (CDX) tumours. METHODS: CDX tumours using strong oestrogen receptor (ER)-positive, Her2-negative (MCF7) and weak ER-positive, Her2 equivocal (T47D) breast cancer cell lines were fixed for various times ranging from 1 to 336 hours in 10% neutral buffered formalin...
March 23, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28334713/pulsed-dose-rate-brachytherapy-for-the-treatment-of-endometrial-cancer
#15
Francesca De Felice, Rossella Caiazzo, Ilaria Benevento, Daniela Musio, Filippo Rubini, Vincenzo Tombolini
Endometrial cancer (EC) is the most frequent gynecologic malignancy. The aim of this review is to outline clinical practice recommendations, to suggest a technical solution, and to advise doses selection for pulsed-dose rate (PDR) brachytherapy in EC. Electronic bibliographic databases, including PubMed, clinicaltrials.gov, and the American Society of Clinical Oncology (ASCO) Meeting Library, were searched for articles in English. Clinical guidelines and systematic reviews were also considered. The appropriate therapeutic approach should consider risk factors for tumor relapse and PDR brachytherapy and have a convincing role in this multidisciplinary scenario...
March 24, 2017: Oncology
https://www.readbyqxmd.com/read/28322840/med1-may-explain-the-interaction-between-receptor-tyrosine-kinases-and-er%C3%AE-66-in-the-complicated-network-of-tamoxifen-resistance
#16
REVIEW
Sepideh Mansouri, Fateme Naghavi-Al-Hosseini, Leila Farahmand, Keivan Majidzadeh-A
According to the American Society of Clinical Oncology or ASCO's clinical practice guidelines, administration of Tamoxifen for hormone receptor positive patients improved outcomes. However, many studies have been conducted in this issue, with the rise of Tamoxifen resistance in recent decades. There are many alternative growth cascades that are activated in Tamoxifen resistant cells. The most common and well characterized components of such a resistant network are receptor tyrosine kinases, or RTKs, which can influence many other cellular processes...
June 5, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28306372/standardized-criteria-for-palliative-care-consultation-on-a-solid-tumor-oncology-service-reduces-downstream-health-care-use
#17
Kerin Adelson, Julia Paris, Jay R Horton, Lorena Hernandez-Tellez, Doran Ricks, R Sean Morrison, Cardinale B Smith
PURPOSE: Hospitalized patients with advanced cancer have a high symptom burden and need for support. Integration of palliative care (PC) improves symptom control and decreases unwanted health care use, yet many patients are never offered these services. In 2016, ASCO called for incorporation of PC into oncologic care for all patients with metastatic cancer. To improve the quality of cancer care, we developed standardized criteria, or triggers, for PC consultation on the inpatient solid tumor service...
March 17, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28290458/from-the-meeting-orlando-plays-host-to-the-2017-asco-genitourinary-cancer-symposium
#18
Annette Fenner
No abstract text is available yet for this article.
March 14, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28276859/meta-analysis-of-randomized-controlled-trials-for-the-incidence-and-risk-of-fatal-adverse-events-in-cancer-patients-treated-with-ipilimumab
#19
Jianhong Zhu, Junyan Wu, Guocheng Li, Jianfang Li, Yin Lin, Zhichao He, Chen Su, Wenxia Zhao, Qianqian Wu, Zepeng Chen, Kaifeng Qiu
BACKGROUND: Ipilimumab is a fully human immunoglobulin G1 monoclonal antibody that increases antitumor T-cell responses. We conducted a meta-analysis of randomized controlled trials (RCTs) to evaluate the risk of FAEs associated with ipilimumab. METHODS: We searched PubMed, EMBASE, and ASCO meeting abstract up to September 2016 for RCT comparing ipilimumab with no ipilimumab on cancer patients. Incidence rates, relative risk ratios (RRs), and 95% confidence intervals (CIs) were calculated using fixed- or random effects models...
April 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28275115/safety-and-tolerability-of-pd-1-pd-l1-inhibitors-compared-with-chemotherapy-in-patients-with-advanced-cancer-a-meta-analysis
#20
REVIEW
Tomohiro F Nishijima, Shlomit S Shachar, Kirsten A Nyrop, Hyman B Muss
BACKGROUND: Compared with chemotherapy, significant improvement in survival outcomes with the programmed death receptor-1 (PD-1) inhibitors nivolumab and pembrolizumab and the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab has been shown in several types of advanced solid tumors. We conducted a systematic review and meta-analysis to compare safety and tolerability between PD-1/PD-L1 inhibitors and chemotherapy. METHODS: PubMed and American Society of Clinical Oncology (ASCO) databases were searched 1966 to September 2016...
April 2017: Oncologist
keyword
keyword
33466
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"